Staphylococcus lugdunensis is a coagulase-negative staphylococcus belonging to the human commensal cutaneous flora, and has been little studied in the field of prosthetic joint infections. However, it shares many virulence traits with Staphylococcus aureus, including many adhesins and its ability to form biofilm, and the few series of cases reports a significant failure rate.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Rate of PJI infection with Staphylococcus lugdunensis
Timeframe: between 2010 and 2020
Description of PJI infection with Staphylococcus lugdunensis : type
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Description of PJI infection with Staphylococcus lugdunensis : evolution
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Description of patients with PJI infection due to Staphylococcus lugdunensis
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Description of patients with PJI infection due to Staphylococcus lugdunensis : follow up
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Description of patients with PJI infection due to Staphylococcus lugdunensis : medical treatment
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Description of patients with PJI infection due to Staphylococcus lugdunensis : surgical treatment
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
rate of treatment failure
Timeframe: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption